Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

6,741 total articles

Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Maze Therapeutics announced positive topline results from its Phase 2 HORIZON trial showing clinical proof-of-concept for MZE829 in APOL1-mediated kidney disease (AMKD). The company plans to advance MZE829 into pivotal trials and start two Phase 2 trials in 2026 for MZE782 targeting phenylketonuria (PKU) and chronic kidney disease (CKD). Maze also …

Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

Maze Therapeutics reported promising topline results from its Phase 2 HORIZON trial of MZE829, an oral dual-mechanism APOL1 inhibitor targeting APOL1-mediated kidney disease. Treatment resulted in a 35.6% mean reduction in proteinuria (uACR) at week 12 across a broad AMKD patient population, with enhanced efficacy in FSGS patients (61.8% reduction)…

Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.

Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced a significant board restructuring led by majority stockholders Inscobee Inc. and Apimeds Korea, who removed several directors and appointed new ones, including a new CEO. This followed disagreements over a prior merger with MindWave Innovations, with MindWave disputing the board chang…

Picard Medical Reports Full Year 2025 Financial Results

Picard Medical Reports Full Year 2025 Financial Results

Picard Medical, parent company of SynCardia Systems, reported revenue growth of 12.5% in 2025 with total revenue of $4.9 million. Despite an operating loss of $13.3 million, the company improved its operating loss and increased cash reserves significantly following successful equity and debt financing. The SynCardia Total Artificial Heart continues…

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics has dosed the first patient in a Phase 1b trial evaluating the combination of their oral IKZF1/3 degrader cemsidomide with elranatamab (ELREXFIO®), an FDA-approved bispecific antibody, in patients with relapsed or refractory multiple myeloma. The trial aims to establish the optimal dose, assess safety, tolerability, and preliminary …

Energous Wireless Power Solutions Reports Fiscal Year 2025 Results

Energous Wireless Power Solutions Reports Fiscal Year 2025 Results

Energous Corporation announced strong fiscal year 2025 results, reporting $5.6 million in revenue — a 633% increase from 2024 — and the lowest quarterly net loss since 2013. The company achieved four consecutive quarters of revenue growth, expanded production capacity in the U.S., and secured a large expansion with a Fortune 10 retailer. Operationa…

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

Beam Therapeutics announced updated clinical data from its ongoing Phase 1/2 trial of BEAM-302, a gene-editing therapy for Alpha-1 Antitrypsin Deficiency (AATD). The therapy showed a well-tolerated safety profile and durable increases in functional AAT protein with significant reduction in mutant Z-AAT after a single dose. Beam selected 60 mg as th…

Winnebago Industries Reports Second Quarter Fiscal 2026 Results

Winnebago Industries Reports Second Quarter Fiscal 2026 Results

Winnebago Industries, a leading manufacturer in outdoor recreation products, reported a 6% increase in net revenues to $657.4 million for Q2 Fiscal 2026 and significant profitability improvements, including a 42.1% rise in adjusted earnings per diluted share to $0.27. The company improved operating income by 50.7% to $11.8 million and executed a $1…

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

Merck & Co., Inc. announced an agreement to acquire Terns Pharmaceuticals, a clinical-stage oncology company, for approximately $6.7 billion. The acquisition focuses on Terns' lead investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor, TERN-701, which is in Phase 1/2 trials for chronic myeloid leukemia (CML). The deal reflects Merck's…

BOSS Zhipin Continues Share Repurchase Program; Cumulative Repurchases Reach Nearly RMB450 Million in FY26

BOSS Zhipin Continues Share Repurchase Program; Cumulative Repurchases Reach Nearly RMB450 Million in FY26

Kanzhun Limited, operating as BOSS Zhipin, announced the continuation and expansion of its share repurchase program, having spent nearly RMB450 million in 2026 to buy back shares. The board increased repurchase authorization to US$400 million through August 2027 and committed to allocating at least 50% of adjusted net income annually for dividends …

ADMA Biologics Addresses Misleading Short-Seller Report

ADMA Biologics Addresses Misleading Short-Seller Report

ADMA Biologics, a U.S.-based biopharmaceutical company specializing in plasma-derived biologics for immune deficiencies, has publicly addressed a negative short-seller report issued by Culper Research. The company refutes the report's assertions as speculative and false, emphasizing its compliance with regulatory standards and ongoing review of the…

Comstock to Participate in the Lytham Partners 2026 Industrials & Basic Materials Investor Summit on April 1, 2026

Comstock to Participate in the Lytham Partners 2026 Industrials & Basic Materials Investor Summit on April 1, 2026

Comstock Inc. announced that it will participate in a webcast presentation at the Lytham Partners 2026 Industrials & Basic Materials Investor Summit scheduled for April 1, 2026. The company continues to focus on innovative technologies that extract and recycle critical metals from end-of-life photovoltaics, supporting clean energy systems.

Viomi Technology Co., Ltd Reports Second Half and Full Year 2025 Unaudited Financial Results and Announces Special Dividend

Viomi Technology Co., Ltd Reports Second Half and Full Year 2025 Unaudited Financial Results and Announces Special Dividend

Viomi Technology Co., Ltd, a NASDAQ-listed Chinese home water solutions company, announced unaudited financial results for H2 and full-year 2025, showing a 14.6% revenue increase to RMB2.43 billion for the year despite a 25.9% revenue decline in the second half. Net income dipped slightly by 1.9% year-over-year to RMB141.6 million. The company attr…